Abstract
Carbamazepine (CBZ) has been extensively used in the treatment of epilepsy, as well as in the treatment of neuropathic pain and affective disorders. However, the mechanisms of action of this drug are not completely elucidated and are still a matter of debate. Since CBZ is not very effective in some epileptic patients and may cause several adverse effects, several antiepileptic drugs have been developed by structural variation of CBZ, such as oxcarbazepine (OXC), which is used in the treatment of epilepsy since 1990. (S)-(−)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide (BIA 2-093) and 10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-5-carboxamide (BIA 2-024), which were recently developed by BIAL, are new putative antiepileptic drugs, with some improved properties. In this review, we will focus on the mechanisms of action of CBZ and its derivatives, OXC, BIA 2-093 and BIA 2-024. The available data indicate that the anticonvulsant efficacy of these AEDs is mainly due to the inhibition of sodium channel activity.
Similar content being viewed by others
REFERENCES
Sindrup, S. H. and Jensen, T. S. 1999. Efficacy of pharmacological treatments of neuropathic pain: un update and effect related to mechanism of drug action. Pain 83:389–400.
Albani, F., Riva, R., and Baruzzi, A. 1995. Carbamazepine clinical pharmacology: a review. Pharmacopsychiat. 28:235–244.
Kerr, B. M. and Levy, R. H. 1989. Carbamazepine. Carbamazepine epoxide. Pages 505–520, in Levy, R., Mattson, R., Meldrum, B., Penry, J. K., and Dreifuss, F. E. (eds.), Antiepileptic drugs, Raven Press, New York.
Shorvon, S. D. 1996. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 28:S64–S70.
Yasui, N., Otani, K., Kaneko, S., Shimoyama, R., Ohkubo, T., and Sugawara, K. 1997. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. Int. Clin. Psychopharmacol. 12:225–229.
Emilien, G. and Maloteaux, J. M. 1988. Pharmacological management of epilepsy. Mechanism of action, pharmacokinetic drug interactions, and new drug discovery possibilities. Int. J. Clin. Pharmacol. Ther. 36:181–194.
Tateishi, T., Asoh, M., Nakura, H., Watanabe, M., Tanaka, M., Kumai, T., and Kobayashi, S. 1999. Carbamazepine induces multiple cytochrome P450 subfamilies in rats. Chem.-Biol. Int. 117:257–268.
Elger, C. E. and Bauer, J. 1998. New antiepileptic drugs in epileptology. Neuropsychobiology 38:145–148.
Loiseau, P. and Duché, P. 1995. Carbamazepine. Clinical use. Pages 555–566, in Levy, R. H., Mattson, R. H., and Meldrum, M. S. (eds.), Antiepileptic drugs, Raven Press, New York.
Rogawski, M. A. and Porter, R. J. 1990. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:223–286.
Wolfe, J. F., Greenwood, T. D., and Mulheron, J. M. 1998. Recent trends in the development of new anti-epileptic drugs. Exp. Opin. Ther. Patents 8:361–381.
Benes, J., Parada, A., Figueiredo, A. A., Alves, P. C., Freitas, A. P., Learmonth, D. A., Cunha, R. A., Garrett, J., and Soaresda-Silva, P. 1999. Anticonvulsant and sodium channel-blocking properties of novel 10,11–dihydro-5H-dibenz[b, f ]azepine-5–carboxamide derivatives. J. Med. Chem. 42:2582–2587.
Benes, J., Soares-da-Silva, P., and Learmonth, D. 1999. Derivatives of 10,11–dihydro-10–oxo-5H-dibenz[b,f ]azepine-5–carboxamide. United States Patent. Patent Number 5,866,566.
McLean, M. J. and Macdonald, R. L. 1986. Carbamazepine and 10,11–epoxy-carbamazepine produce use-and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 238:727–732.
Elliott, P. 1990. Action of antiepileptic and anaesthetic drugs on Na-and Ca-spikes in mammalian non-myelinated axons. Eur. J. Pharmacol. 175:155–163.
Macdonald, R. L. and Kelly, K. M. 1993. Antiepileptic drug mechanism of action. Epilepsia 34:S1–S8.
Willow, M., Gonoi, T., and Catterall, W. A. 1985. Voltage clamp analysis of the inhibitory action of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol. Pharmacol. 27:549–558.
Rush, A. M. and Elliott, J. R. 1997. Phenytoin and carbamazepine-Differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia. Neurosci. Lett. 226:95–98.
Courtney, K. R. and Etter, E. F. 1983. Modulated anticonvulsant block of sodium channels in nerve and muscle. Eur. J. Pharmacol. 88:1–9.
Kuo, C. C., Chen, R. S., Lu, L., and Chen, R. C. 1997. Carbamazepine inhibition of neuronal Na+ currents-quantitative distinction from phenytoin and possible therapeutic implications. Mol. Pharmacol. 51:1077–1083.
Willow, M. and Catteral, W. A. 1982. Inhibition of binding of [3H]batrachotoxinin A 20–α-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 22:627–635.
Willow, M., Kuenzel, E. A., and Catterall, W. A. 1984. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 25:228–234.
Taylor, C. P. 1996. Voltage-gated Na+ channels as targets for anticonvulsant, analgesic and neuroprotective drugs. Curr. Pharma. Design 2:375–388.
Walden, J., Grunze, H., Bingmann, D., Liu, Z., and Düsing, R. 1992. Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. Eur. Neuropsychopharmacol. 2:455–462.
Walden, J., Grunze, H., Mayer, A., DÚsing, R., Schirrmacher, K., Liu, Z., and Bingmann, D. 1993. Calcium-antagonistic effects of carbamazepine in epilepsies and affective psychosis. Neuropsychobiol. 27:171–175.
Schirrmacher, K., Mayer, A., Walden, J., Dusing, R., and Bingmann, D. 1993. Effects of carbamazepine on action potentials and calcium currents in rat spinal ganglion cells in vitro. Neuropsychobiol. 27:176–179.
Schirrmacher, K., Mayer, A., Walden, J., Dusing, R., and Bingmann, D. 1995. Effects of carbamazepine on membrane properties of rat sensory spinal ganglion cells in vitro. Eur. Neuropsychopharmacol. 5:501–507.
Yoshimura, R., Yanagihara, N., Terao, T., Minami, K., Abe, K., and Izumi, F. 1998. Inhibition by carbamazepine of various ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Naunyn Schmiedeberg's Arch. Pharmacol. 352:297–303.
Yoshimura, R., Yanagihara, N., Terao, T., Minami, K., Toyohira, Y., Ueno, S., Uezono, Y., Abe, K., and Izumi, F. 1998. An active metabolite of carbamazepine, carbamazepine-10,11–epoxide, inhibits ion channel-mediated catecholamine secretion in cultured bovine adrenal medullary cells. Psychopharmacol. 135:368–373.
Schumacher, T. B., Beck, H., Steinhäuser, C., Schramm, J., and Elger, C. E. 1998. Effects of phenytoin, carbamazepine, and gabapentin on calcium channels in hippocampal granule cells from patients with temporal lobe epilepsy. Epilepsia 39:355–363.
Ambrósio, A. F., Silva, A. P., Malva, J. O., Soares-da-Silva, P., Carvalho, A. P., and Carvalho, C. M. 1999. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 38:1349–1359.
Zona, C., Tancredi, V., Palma, E., Pirrone, G. C., and Avoli, M. 1990. Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine. Can. J. Physiol. Pharmacol. 68:545–547.
Sayer, R. J., Brown, A. M., Schwindt, P. C., and Crill, W. E. 1993. Calcium currents in acutely isolated human neocortical neurons. J. Neurophysiol. 69:1596–1606.
Kito, M., Machara, M., and Watanabe, K. 1994. Antiepileptic drugs-calcium current interaction in cultured human neuroblastoma cells. Seizure 3:141–149.
Ambrósio, A. F., Silva, A. P., Malva, J. O., Soares-da-Silva, P., Carvalho, A. P., and Carvalho, C. M. 2001. Inhibition of glutamate release by BIA 2–093 and BIA 2–024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem. Pharmacol. 61:1271–1275.
Olpe, H., Kolb, C. N., Hausdorf, A., and Haas, H. L. 1991. 4–aminopyridine and barium chloride attenuate the antiepileptic effect of carbamazepine in hippocampal slices. Experientia 47:254–257.
Matsumoto, Y., Enomoto, K., Moritake, K., and Maeno, T. 1998. Effects of carbamazepine on nerve activity and transmitter release in neuroblastoma-glioma hybrid cells and the frog neuromuscular junction. Cell Biol. Toxicol. 14:191–198.
Dreixler, J. C., Bian, J., Cao, Y., Roberts, M. T., Roizen, J. D., and Houamed, K. M. 2000. Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur. J. Pharmacol. 401:1–7.
Wooltorton, J. R. A. and Mathie, A. 1993. Block of potassium currents in rat isolated sympathetic neurones by tricyclic antidepressants and structurally related compounds. Br. J. Pharmacol. 110:1126–1132.
Lee, K., McKenna, F., Rowe, I. C., and Ashford, M. L. 1997. The effects of neuroleptic and tricyclic compounds on BKCa channel activity in rat isolated cortical neurones. Br. J. Pharmacol. 121:1810–1816.
Rundfeldt, C. 1997. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. J. Pharmacol. 336:243–249.
Gasser, T., Reddington, M., and Schubert, P. 1988. Effect of carbamazepine on stimulus-evoked Ca2+ fluxes in rat hippocampal slices and its interaction with A1-adenosine receptors. Neurosci. Lett. 91:189–193.
Weir, R. L., Anderson, S. M., and Daly, J. W. 1990. Inhibition of N6-[3H]cyclohexyladenosine binding by carbamazepine. Epilepsia 31:503–512.
Van Calker, D., Steber, R., Klotz, K. N., and Greil, W. 1991. Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. Eur. J. Pharmacol. 206:285–290.
Biber, K., Fiebich, B. L., Gebicke-Harter, P., and Van Calker, D. 1999. Carbamazepine-induced upregulation of adenosine A1-receptors in astrocyte cultures affects coupling to the phosphoinositol signaling pathway. Neuropsychopharmacology 20:271–278.
Daval, J. L., Deckert, J., Weiss, S. R., Post, R. M., and Marangos, P. J. 1989. Upregulation of adenosine A1 receptors and forskolin binding sites following chronic treatment with caffeine or carbamazepine: a quantitative autoradiographic study. Epilepsia 30:26–33.
Skerrit, J. H., Davies, L. P., and Johnston, G. A. (1983) Interactions of the anticonvulsant carbamazepine with adenosine receptors. 1. Neurochemical studies. Epilepsia 24:634–642.
Okada, M., Hirano, T., Mizuno, K., Chiba, T., Kawata, Y., Kiryu, K., Wada, K., Tasaki, H., and Kaneko, S. 1997. Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res. 28:143–153.
Larkin, J. G., Thompson, G. G., Scobie, G., Drennan, J. E., and Brodie, M. J. 1991. Lack of major effects on mouse brain adenosine A1 receptors of oral carbamazepine and calcium antagonists. Epilepsia 32:729–734.
Malhotra, J. and Gupta, Y. K. 1999. Effect of adenosinergic modulation on the anticonvulsant effect of phenobarbitone and carbamazepine. Methods Find. Exp. Clin. Pharmacol. 21:79–83.
Yan, Q. S., Mishra, P. K., Burger, R. L., Bettendorf, A. F., Jobe, P. C., and Dailey, J. W. 1992. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J. Pharmacol. Exp. Ther. 261:652–659.
Dailey, J. W., Reith, M. E. A., Yan, Q. S., Li, M. Y., and Jobe, P. C. 1997. Carbamazepine increases extracellular serotonin concentration-Lack of antagonism by tetrodotoxin or zero Ca2+ Eur. J. Pharmacol. 328:153–162.
Dailey, J. W., R eith, M. E. A., Yan, Q. S., Li, M. Y., and Jobe, P. C. 1997. Anticonvulsant doses of carbamazepine increase hippocampal extracellular serotonin in genetically epilepsyprone rats-Dose response relationships. Neurosci. Lett. 227:13–16.
Dailey, J. W., Reith, M. E. A., Steidley, K. R., Milbrandt, J. C., and Jobe, P. C. 1998. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 39:1054–1063.
Okada, M., Kawata, Y., Mizuno, K., Wada, K., Kondo, T., and Kaneko, S. 1998. Interaction between Ca2+ K+ carbamazepine and zonizamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Brit. J. Pharmacol. 124:1277–1285.
Southam, E., Kirkby, D., Higgins, G. A., and Hagan, R. M. 1998. Lamotrigine inhibits monoamine uptake in vitro and modulates 5–hydroxytryptamine uptake in rats. Eur. J. Pharmacol. 358:19–24.
Pranzatelli, M. R. 1988. Effect of antiepileptic and antimyoclonic drugs on serotonin receptors in vitro. Epilepsia 29:412–419.
Elphick, M. 1989. Effects of carbamazepine on dopamine function in rodents. Psychopharmacology 99:532–536.
Kowalik, S., Levitt, M., and Barkai, A. I. 1984. Effects of carbamazepine and anti-depressant drugs on endogenous catecholamine levels in the cerebroventricular compartment of the rat. Psychopharmacology 83:169–171.
Barros, H. M., Braz, S., and Leite, J. R. 1986. Effect of carbamazepine on dopamine release and reuptake in rat striatal slices. Epilepsia 27:534–537.
Baf, M. H., Subhash, M. N., Lakshmana, K. M., and Rao, B. S. 1994. Alterations in monoamine levels in discrete regions of rat brain after chronic administration of carbamazepine. Neurochem. Res. 19:1139–1143.
Ichikawa, J. and Meltzer, H. Y. 1999. Valproate and carbamazepine increase prefrontal dopamine release by 5–HT1A receptor activation. Eur. J. Pharmacol. 380:R1–R3.
Post, R. M., Rubinow, D. R., Uhde, T. W., Ballenger, J. C., and Linnoila, M. 1986. Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness. Arch. Gen. Psychiatry 43:392–396.
Rogawski, M. A. 1995. Excitatory amino acids and seizures. Pages 219–237, in Stone, T. W. (eds.), CNS neurotransmitters and neuromodulators-Glutamate, CRC Press, London.
Olpe, H.-R., Baudry, M., and Jones, R. S. G. 1985. Electrophysiological and neurochemical investigations on the action of carbamazepine on the rat hippocampus. Eur. J. Pharmacol. 110:71–80.
Crowder, J. M. and Bradford, H. F. 1987. Common anticonvulsants inhibit Ca2+ uptake and amino acid neurotransmitter release in vitro. Epilepsia 28:378–382.
Waldmeier, P. C., Baumann, P. A., Wicki, P., Feldtrauer, J. J., Stierlin, C., and Schmutz, M. 1995. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 45:1907–1913.
Waldmeier, P. C., Martin, P., Stocklin, K., Portet, C., and Schmutz, M. 1996. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn Schmiedeberg's Arch. Pharmacol. 354:164–172.
Lingamaneni, R. and Hemmings Jr., H. C. 1999. Effects of anticonvulsants on veratridine-and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci. Lett. 276:127–130.
Lampe, H. and Bigalpe, H. 1990. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1:26–28.
Cai, Z. and McCaslin, P. P. 1992. Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate-and N-methyl-D-aspartateinduced intracellular Ca2+ levels in neuronal culture. Eur. J. Pharmacol. 219:53–57.
Lancaster, J. M. and Davies, J. A. 1992. Carbamazepine inhibits NMDA-induced depolarization in cortical wedges prepared from DBA/2 mice. Experientia 48:751–753.
Sofia, R. D., Gordon, R., Gels, M., and Diamantis, W. 1994. Comparative effects of felbamate and other compounds on N-methyl-D-aspartic acid-induced convulsions and lethality in mice. Pharmacol. Res. 29:139–144.
Hough, C. J., Irwin, R. P., Gao, X.-M., Rogawski, M. A., and Chuang, D.-M. 1996. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J. Pharmacol. Exp. Ther. 276:143–149.
Phillips, L., Martin, K. F., Thompson, K. S. J., and Heal, D. J. 1997. Weak blockade of AMPA receptor-mediated depolarizations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine. Eur. J. Pharmacol. 337:189–195.
Grant, K. A., Snell, L. D., Rogawski, M. A., Thurkauf, A., and Tabakoff, B. 1992. Comparison of the effects of the uncompetitive N-methyl-D-aspartate antagonist (6)-5–aminocarbonyl-10,11–dihydro-5H-dibenzo [a,d ] cyclohepten-5,10–imine (ADCI) with its structural analogue dizocilpine (MK-801) and carbamazepine on ethanol withdrawal seizures. J. Pharmacol. Exp. Ther. 260:1017–1022.
Ambrósio, A. F., Silva, A. P., AraÚjo, I., Malva, J. O., Soaresda-Silva, P., Carvalho, A. P., and Carvalho, C. M. 2000. Neurotoxic/ neuroprotective profile of carbamazepine and two new putative antiepileptic drugs, BIA 2–093 and BIA 2–024. Eur. J. Pharmacol. 406:191–201.
Marangos, P. J., Post, R. M., Patel, J., Zander, K., Parma, A., and Weiss, S. 1983. Specific and potent interactions of carbamazepine with brain adenosine receptors. Eur. J. Pharmacol. 93:175–182.
Bender, A. S. and Hertz, L. 1985. Binding of [3H]Ro 5–4864 in primary cultures of astrocytes. Brain Res. 341:41–49.
Weiss, S. R., Post, R. M., Patel, J., and Marangos, P. J. 1985. Differential mediation of the anticonvulsant effects of carbamazepine and diazepam. Life Sci. 36:2413–2419.
Weizman, A., Tanne, Z., Karp, L., Martfield, Y., Tyano, S., and Gavish, M. 1987. Carbamazepine up-regulates the binding of [3H]PK 11195 to platelets of epileptic patients. Eur. J. Pharmacol. 141:471–474.
Ferrarese, C., Marzorati, C., Perego, M., Bianchi, G., Cavarretta, R., Pierpa, C., Moretti, G., and Frattola, L. 1995. Effect of anticonvulsant drugs on peripheral benzodiazepine receptors of human lymphocytes. Neuropharmacology 34:427–431.
Ludvig, N., Mishra, P. K., and Jobe, P. C. Dibutyryl cyclic AMP has epileptogenic potential in the hippocampus of freely behaving rats: a combined EEG-intracerebral microdialysis study. Neurosci. Lett. 141:187–191.
Hudson, C. J., Young, L. T., Li, P. P., and Warsh, J. J. 1993. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 13:278–293.
Myllyla, V. V. 1976. Effect of convulsions and anticonvulsive drugs on cerebrospinal fluid cyclic AMP in rabbits. Eur. Neurol. 14:97–107.
Palmer, G. C., Jones, D. J., Medina, M. A., and Stavinoha, W. B. 1979. Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain. Epilepsia 20: 95–104.
Lewin, E., and Bleck, V. 1977. Cyclic AMP accumulation in cerebral cortical slices: effect of carbamazepine, phenobarbital, and phenytoin. Epilepsia 18:237–242.
Ferrendelli, J. A. and Kinscherf, D. A. 1979. Inhibitory effects of anticonvulsant drugs on cyclic nucleotides accumulation in the brain. Ann. Neurol. 5:533–538.
Elphick, M., Taghavi, Z., Powell, T., and Godfrey, P. P. 1990. Chronic carbamazepine down-regulates adenosine A2 receptors: studies with the putative selective adenosine antagonists PD115,199 and PD116,948. Psychopharmacology 100:522–529.
Palmer, G. C., Jones, D. J., Medina, M. A., and Stavinoha, W. B. 1979. Anticonvulsant drug actions on in vitro levels of cyclic AMP in the mouse brain. Epilepsia 20:95–104.
Post, R. M., Ballenger, J. C., Uhde, T. W., Smith, C., Rubinow, D. R., and Bunney, W. R. Jr 1982. Effect of carba-mazepine on cyclic nucleotides in CSF of patients with affective ilness. Biol. Psychiatry 17:1037–1045.
Chen, G., Pan, B. S., Hawver, D. B., Wright, C. B., and Potter, W. Z. 1996. Attenuation of cyclic-AMP production by carbamazepine. J. Neurochem. 67:2079–2086.
Afanas'ev, I., Kudrin, V., Rayevsky, K. S., Varga, V., Saransaari, P., and Oja, S. S. 1999. Lamotrigine and carbamazepine affect differently the release of D-[3H]aspartate from mouse cerebral cortex slices: involvement of NO. Neurochem. Res. 24:1153–1159.
Wamil, A. W., Portet, C., Jensen, P. K., Schmutz, M., and McLean, M. J. 1991. Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in culture. Epilepsia 32:65–66.
McLean, M. J., Schmutz, M., Wamil, A. W., Olpe, H. R., Portet, C., and Fedmann, K. F. 1994. Oxcarbazepine: mechanisms of action. Epilepsia, 35:S55–S59.
Wamil, A. W., Schmutz, M., Portet, C., Feldmann, K. F., and McLean, M. J. 1994. Effects of oxcarbazepine and 10–hydroxycarbazepine on action potential firing and generalized seizures. Eur. J. Pharmacol. 271:301–308.
Schmutz, M., Brugger, F., Gentsch, C., McLean, M. J., and Olpe, H. R. 1994. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 35:S47–S50.
Stefani, A., Pisani, A., De Murtas, M., Mercuri, N. B., Marciani, M. G., and Calabresi, P. 1995. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 336:997–1002.
Deckert, J., Berger, W., Kleopa, K., Heckers, S., Ransmayr, G., Heisen, H., Beckmann, H., and Riederer, P. 1993. Adenosine A1 receptors in human hippocampus: inhibition of [3H]8–cyclopentyl-1,3–dipropylxanthine binding by antagonistic drugs. Neurosci. Lett. 150:191–194.
Fujiwara, Y., Sato, M., and Otsuki, S. 1986. Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacology 90:332–335.
Joca, S. R., Skalisz, L. L., Beijamini, V., Vital, M. A., and Andreatini, R. 2000. The antidepressive-like effect of oxcarbazepine: possible role on dopaminergic neurotransmission. Eur. Neuropsychopharmacol. 10:223–228.
Ambrósio, A. F. 2000. Mechanisms of action of antiepileptic drugs and neurotoxicity in hippocampus. PhD Thesis.
Learmonth, D. A., Benes, J., Parada, A., Hainzl, D., Beliaev, A., Bonifácio, M. J., Matias, P. M., Carrondo, M. A., Garrett, J. and Soares-da-Silva, P. 2001. Synthesis, anticonvulsant properties and pharmacokinetic profile of novel 10,11–dihydro-10–oxo-5H-dibenz/b,f/azepine-5–carboxamide derivatives. Eur. J. Med. Chem. 36:227–236.
Hainzl, D., Parada, A., Soares-da-Silva, P. 2001. Metabolism of two new antiepileptic drugs and their principal metabolites S(1)-and R(2)-10,11–dihydro-10–hydroxy carbamazepine. Epilepsy Res. 44:197–206.
Bonifácio, M. J. and Soares-da-Silva, P. 2000. Effects of BIA 2–059 and BIA 2–093 on rat brain voltage-dependent sodium channels. Eur. J. Neurosci. 12 (Suppl. 11):11.20, p158.
Bonifácio, M. J., Sheridan, R. D., Parada, A., Cunha, R. A., Patmore, L., Soares-da-Silva, P. 2001. Interaction of the novel anticonvulsant, BIA 2–093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 42:600–608.
Parada, A. and Soares-da-Silva, P. 2000. Effects of BIA 2–093, carbamazepine and oxcarbazepine on transmitter release: an in vitro study. Eur. J. Neurosci. 12 (Suppl. 11):16.15, p250.
Borges, N., Parada, A., and Soares-da-Silva, P. 2000. Effects of BIA 2–093, carbamazepine and oxcarbazepine on transmitter release: a microdialysis study. Eur. J. Neurosci. 12 (Suppl. 11):16.20, p255.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ambrósio, A.F., Soares-da-Silva, P., Carvalho, C.M. et al. Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 27, 121–130 (2002). https://doi.org/10.1023/A:1014814924965
Issue Date:
DOI: https://doi.org/10.1023/A:1014814924965